Review Article
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
Figure 2
Development of precision treatment for solid tumor. Ab: antibody; CTL: cytotoxic T cells; CTLA-4: cytotoxic T lymphocyte-associated antigen-4; DC: dendritic cells; iCART: inhibitory signal-based antigen-specific CART cells; IL-2: interleukin-2; LAK: lymphokine-activated killer cells; NK: natural killer cells; NKT: natural killer T cells; NSCLC: non-small-cell lung cancer; PD-1: programmed death-1; TanCART: tandem CART cells; TIL: tumor-infiltrating lymphocytes.